ACTUATE THERAPEUTICS, INC. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Bios Equity COF, LP | — | Purchase | 71,428 | $7.00 | $499,996 | 196,428 | Jun 27, 2025 |
| BIOS Fund II, LP | — | Purchase | 71,428 | $7.00 | $499,996 | 196,428 | Jun 27, 2025 |
| BIOS Actuate Co-Invest I, LP | — | Purchase | 71,428 | $7.00 | $499,996 | 196,428 | Jun 27, 2025 |
| Bios Clinical Opportunity Fund, LP | — | Sale | 5,314 | $8.00 | $42,512 | 300,143 | Aug 14, 2024 |
| BIOS Capital Management, LP | — | Sale | 17,361 | $8.00 | $138,888 | 980,433 | Aug 14, 2024 |
| BIOS Fund II, LP | — | Sale | 17,361 | $8.00 | $138,888 | 980,433 | Aug 14, 2024 |
| Kairos-Actuate SPV, L.P. | — | Sale | 18,750 | $8.00 | $150,000 | 1,184,795 | Aug 14, 2024 |
| BP Directors, LP | — | C | 573,394 | — | — | 573,394 | Aug 14, 2024 |
| BIOS Equity Partners III, LP | — | Purchase | 375,000 | $8.00 | $3,000,000 | 1,259,427 | Aug 14, 2024 |
| BIOS Fund II QP, LP | — | C | 61,857 | — | — | 61,857 | Aug 14, 2024 |